Etonorgestrel: Difference between revisions
(Created page with "{{Unreferenced stub|auto=yes|date=December 2009}} {{Drugbox | verifiedrevid = 461098012 | IUPAC_name = (8''S'',9''R'',10''S'',13''S'',14''S'',17''R'')-13-Ethyl-17-ethynyl-17-h...") |
No edit summary |
||
| Line 60: | Line 60: | ||
{{CMG}}; {{AE}} {{Alonso}} | {{CMG}}; {{AE}} {{Alonso}} | ||
'''Etonogestrel''' is a [[steroid]]al [[progestin]] used in [[hormonal contraceptive]]s, most notably the | '''Etonogestrel''' is a [[steroid]]al [[progestin]] used in [[hormonal contraceptive]]s, most notably the subdermal implant Nexplanon and the [[vaginal ring]] [[NuvaRing]]. | ||
Etonogestrel is the [[active metabolite]] of the inactive prodrug [[desogestrel]], one of two third-generation progestins found in some [[epidemiological study|epidemiological studies]] of [[combined oral contraceptive pill]]s to be associated with a higher risk of [[venous thrombosis]] than combined oral contraceptive pills containing certain second-generation progestins. Because [[steroid hormone|hormone]]s are released continuously from NuvaRing, peak and total [[estrogen]] and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of [[blood clot]]s. | Etonogestrel is the [[active metabolite]] of the inactive prodrug [[desogestrel]], one of two third-generation progestins found in some [[epidemiological study|epidemiological studies]] of [[combined oral contraceptive pill]]s to be associated with a higher risk of [[venous thrombosis]] than combined oral contraceptive pills containing certain second-generation progestins. Because [[steroid hormone|hormone]]s are released continuously from NuvaRing, peak and total [[estrogen]] and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of [[blood clot]]s. | ||
| Line 66: | Line 66: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hormonal contraception]] | |||
Revision as of 16:30, 31 July 2014
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a604032 |
| Routes of administration | Subdermal as slow-release implant |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Hepatic (P450 3A4) |
| Elimination half-life | 25 hours |
| Excretion | Urinary (majority) and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H28O2 |
| Molar mass | 324.457 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]
Etonogestrel is a steroidal progestin used in hormonal contraceptives, most notably the subdermal implant Nexplanon and the vaginal ring NuvaRing.
Etonogestrel is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.